A Phase I Study of a Combination of Liposomal Irinotecan and Veliparib in Solid Tumors.

Meredith LaRoseRoisin M ConnollyCiara C O'SullivanVamsidhar VelchetiRasa VilimasKatherine GanoSusan E BatesYves PommierAnish Thomas

Published in: The oncologist (2023)

The clinical trial was terminated due to high frequency of unacceptable gastrointestinal toxicities, which precluded dose escalation of veliparib in combination with nal-IRI (ClinicalTrials.gov Identifier: NCT02631733).

Keyphrases

high frequency
clinical trial
transcranial magnetic stimulation
open label
study protocol
phase ii
double blind